INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 410m ago
House PTR10m ago
SEC 13F9m ago
Robinhood Chain9m ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02FWFogarty Patrick W0B / 206S206 trades$1.10M
  3. 03SPSaba Capital Management, L.P.65B / 19S · 11 late84 trades$21.64M
  4. 04NYNissan Yitzhak82B / 0S · 79 late82 trades$2.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SJSheena Jonathan0B / 45S45 trades$3.01M
  9. 09SISarowitz Steven I2B / 34S36 trades$22.46M
  10. 10SLSpeiser Michael L0B / 35S35 trades$14.00M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 179 insiders$893K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

72,770 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
41
PJ
Phelan Kenneth JDirector
HPSJOHN HANCOCK PREFERRED INCOME FUND III
Open-market purchase
BUY$10K
683 sh
Jan 26, 2026
Page 1424 of 1820
← PrevNext →
Jan 27, 2026
traded Jan 26, 2026
+1d
SEC Form 4

Evidence

41
FG
Freve Maria GSee Remarks
SYMSymbotic Inc.
Open-market sale
SELL$400K
6,667 sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

41
PJ
Phelan Kenneth JDirector
BTOJOHN HANCOCK FINANCIAL OPPORTUNITIES FUND
Open-market purchase
BUY$10K
270 sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

41
PJ
Phelan Kenneth JDirector
JHSJOHN HANCOCK INCOME SECURITIES TRUST
Open-market purchase
BUY$1,528
130 sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

41
PJ
Phelan Kenneth JDirector
HPIJOHN HANCOCK PREFERRED INCOME FUND
Open-market purchase
BUY$10K
614 sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

41
PJ
Phelan Kenneth JDirector
HEQJohn Hancock Diversified Income Fund
Open-market purchase
BUY$10K
905 sh
Jan 27, 2026Jan 27, 2026
traded Jan 27, 2026
+0dSEC Form 4

Evidence

41
PJ
Phelan Kenneth JDirector
HPFJOHN HANCOCK PREFERRED INCOME FUND II
Open-market purchase
BUY$10K
618 sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

41
PJ
Phelan Kenneth JDirector
JHIJOHN HANCOCK INVESTORS TRUST
Open-market purchase
BUY$10K
730 sh
Jan 27, 2026Jan 27, 2026
traded Jan 27, 2026
+0dSEC Form 4

Evidence

37
PJ
Phelan Kenneth JDirector
JHSJOHN HANCOCK INCOME SECURITIES TRUST
Open-market purchase
BUY$8,541
725 sh
Jan 27, 2026Jan 27, 2026
traded Jan 27, 2026
+0dSEC Form 4

Evidence

36
AK
Alam KamranCHIEF FINANCIAL OFFICER
TSHATaysha Gene Therapies, Inc.
Open-market sale
SELL$375K
79.0K sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC Form 4

Evidence

34
HJ
Howe JolandaSVP, GLOBAL CONTROLLER
MIRMMirum Pharmaceuticals, Inc.
Open-market sale
SELL$81K
842 sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

33
BK
Banks Margaret KatherineDirector
HALHALLIBURTON CO
Open-market sale
SELL$89K
2,600 sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

33
WL
Whitley Laura LDirector
TCBITEXAS CAPITAL BANCSHARES INC/TX
Open-market purchase
BUY$49K
500 sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC Form 4

Evidence

32
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Open-market sale
SELL$423K
89.1K sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC Form 4

Evidence

30
GS
Golten Alex SCHIEF RISK OFFICER
GSGOLDMAN SACHS GROUP INC
Tax withholding
F$2.77M
2,904 sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC Form 4

Evidence

30
WF
Walsh John FCEO-The Americas
ACNAccenture plc
Open-market sale · 10b5-1 plan
SELL$718K
2,600 sh
Jan 27, 2026Jan 27, 2026
traded Jan 27, 2026
+0dSEC Form 4

Evidence

30
KJ
Kuffner JamesCHIEF TECHNOLOGY OFFICER
SYMSymbotic Inc.
Open-market sale
SELL$63K
1,048 sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

29
WL
Whitley Laura LDirector
TCBITEXAS CAPITAL BANCSHARES INC/TX
Open-market purchase
BUY$49K
500 sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

27
RM
Ramani MohitChief Risk Officer
KEYKEYCORP /NEW/
Tax withholding
F$445K
21.1K sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC Form 4

Evidence

27
ME
Michael ElsaDirector
GESGUESS INC
Other acquisition or disposition
J$130K
7,735 sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC Form 4

Evidence

27
LN
Lewis Christopher N.Director
GESGUESS INC
Other acquisition or disposition
J$82K
4,914 sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC Form 4

Evidence

26
HC
Halio CareyGlobal Treasurer
GSGOLDMAN SACHS GROUP INC
Tax withholding
F$1.88M
1,966 sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC Form 4

Evidence

25
AK
Alam KamranCHIEF FINANCIAL OFFICER
TSHATaysha Gene Therapies, Inc.
Open-market sale
SELL$110K
23.8K sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

25
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Open-market sale
SELL$124K
26.9K sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

24
LA
Lee AdriannePresident & CFO
BBBYBED BATH & BEYOND, INC.
Grant or award
A—
6,043 sh
Oct 7, 2025Jan 27, 2026
traded Oct 7, 2025
+112dSEC Form 4

Evidence

24
DM
Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.56M
51.9K sh
Jan 27, 2026Jan 27, 2026
traded Jan 27, 2026
+0dSEC Form 4

Evidence

23
MT
Munsey Joshua ToddChief Financial Officer
AMRAlpha Metallurgical Resources, Inc.
Tax withholding
F$350K
1,515 sh
Jan 25, 2026Jan 27, 2026
traded Jan 25, 2026
+2dSEC Form 4

Evidence

23
WF
Walsh John FCEO-The Americas
ACNAccenture plc
Open-market sale · 10b5-1 plan
SELL$144K
524 sh
Jan 27, 2026Jan 27, 2026
traded Jan 27, 2026
+0dSEC Form 4

Evidence

23
EA
Eidson Charles AndrewDirector, Chief Executive Officer
AMRAlpha Metallurgical Resources, Inc.
Tax withholding
F$846K
3,662 sh
Jan 25, 2026Jan 27, 2026
traded Jan 25, 2026
+2dSEC Form 4

Evidence

23
WF
Walsh John FCEO-The Americas
ACNAccenture plc
Open-market sale · 10b5-1 plan
SELL$119K
429 sh
Jan 27, 2026Jan 27, 2026
traded Jan 27, 2026
+0dSEC Form 4

Evidence

23
WE
Whitehead Jason E.President & COO
AMRAlpha Metallurgical Resources, Inc.
Tax withholding
F$587K
2,541 sh
Jan 25, 2026Jan 27, 2026
traded Jan 25, 2026
+2dSEC Form 4

Evidence

23
WF
Walsh John FCEO-The Americas
ACNAccenture plc
Open-market sale · 10b5-1 plan
SELL$117K
421 sh
Jan 27, 2026Jan 27, 2026
traded Jan 27, 2026
+0dSEC Form 4

Evidence

23
HK
Hogan Catherine KiernanChief Operating Officer
ACNAccenture plc
Open-market sale · 10b5-1 plan
SELL$74K
263 sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

23
HK
Hogan Catherine KiernanChief Operating Officer
ACNAccenture plc
Open-market sale · 10b5-1 plan
SELL$64K
227 sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC Form 4

Evidence

22
CP
Coleman Denis P.Chief Financial Officer
GSGOLDMAN SACHS GROUP INC
Tax withholding
F$2.36M
2,467 sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC Form 4

Evidence

22
A
A-6684 Ltd.10% Owner
TOFBTOFUTTI BRANDS INC
Open-market purchase
BUY$3,439
4,525 sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC Form 4

Evidence

21
GS
Golten Alex SCHIEF RISK OFFICER
GSGOLDMAN SACHS GROUP INC
Option exercise
M—
5,482 sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC Form 4

Evidence

21
HC
Halio CareyGlobal Treasurer
GSGOLDMAN SACHS GROUP INC
Option exercise
M—
4,034 sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC Form 4

Evidence

21
JM
Jordt Raymond MChief Business Officer
ALTAltimmune, Inc.
Option exercise
M—
14.6K sh
Jan 25, 2026Jan 27, 2026
traded Jan 25, 2026
+2dSEC Form 4

Evidence

21
RS
Roberts M ScotChief Scientific Officer
ALTAltimmune, Inc.
Option exercise
M—
14.6K sh
Jan 25, 2026Jan 27, 2026
traded Jan 25, 2026
+2dSEC Form 4

Evidence